Avalo Therapeutics
AVTX
66 hedge funds and large institutions have $195M invested in Avalo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 2 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 2
397% more capital invested
Capital invested by funds: $39.1M → $195M (+$156M)
110% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $659K
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
83% more funds holding
Funds holding: 36 → 66 (+30)
44.03% more ownership
Funds ownership: 72.44% → 116.46% (+44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.06M |
| 2 |
CP
Caligan Partners
New York
|
+$7.17M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.03M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$6.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.63M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.32M |
| 3 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$1.5M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$622K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$331K |
AVTX Hedge Fund Activity: Q3 2025 in Review
66 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2025, worth a combined $195M — up 397% from $39.1M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AVTX positions and 2 closed out — a net gain of 30 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.06M. The largest seller was Deep Track Capital, cutting an estimated $3.63M.
- 66 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2025, up from 36 in Q2 2025.
- Funds reported $195M of Avalo Therapeutics stock for Q3 2025, up 397% quarter-over-quarter.
- 32 funds opened new Avalo Therapeutics positions in Q3 2025 and 2 closed out, a net change of +30 holders.
- The largest Avalo Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $9.06M added.
- The largest Avalo Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $3.63M sold.
Based on aggregated 13F filings for Q3 2025.